Acceder Registro /

Pablo CONESA ZAMORA

Buscador

Santamarina-Garcia M, Brea-Iglesias J, Bramsen JB, Fuentes-Losada M, Caneiro-Gomez FJ, Vazquez-Bueno JA, Lazare-Iglesias H, Fernandez-Diaz N, Sanchez-Rivadulla L, Betancor YZ, Ferreiro-Pantin M, Conesa-Zamora P, Antunez-Lopez JR, Kawazu M, Esteller M, Andersen CL, Tubio JMC, Lopez-Lopez R, Ruiz-Banobre J. MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles. iScience. 2023 Feb 3;26(3):106127. doi: 10.1016/j.isci.2023.106127. eCollection 2023 Mar 17. PubMed PMID: 36879816; PubMed Central PMCID: PMC9984554.
AÑO: 2023; IF: 6.107
Asensi-Canto A, Rodriguez-Braun E, Beltran-Videla A, Hurtado AM, Conesa-Zamora P. Effects of imipramine on cancer patients over-expressing Fascin1; description of the HITCLIF clinical trial. Front Oncol. 2023 Sep 29;13:1238464. doi: 10.3389/fonc.2023.1238464. eCollection 2023. PubMed PMID: 37841433; PubMed Central PMCID: PMC10570506.
AÑO: 2023; IF: 4.7
Muta Y, Linares JF, Martinez-Ordonez A, Duran A, Cid-Diaz T, Kinoshita H, Zhang X, Han Q, Nakanishi Y, Nakanishi N, Cordes T, Arora GK, Ruiz-Martinez M, Reina-Campos M, Kasashima H, Yashiro M, Maeda K, Albaladejo-Gonzalez A, Torres-Moreno D, Garcia-Solano J, Conesa-Zamora P, Inghirami G, Metallo CM, Osborne TF, Diaz-Meco MT, Moscat J. Enhanced SREBP2-driven cholesterol biosynthesis by PKClambda/iota deficiency in intestinal epithelial cells promotes aggressive serrated tumorigenesis. Nat Commun. 2023 Dec 13;14(1):8075. doi: 10.1038/s41467-023-43690-5. PubMed PMID: 38092754.
AÑO: 2023; IF: 16.6
Luengo-Gil G, Conesa-Zamora P. Potential Utility of Induced Translocation of Engineered Bacteria as a Therapeutic Agent for Mounting a Personalized Neoantigen-Based Tumor Immune Response. Glob Chall. 2021 Dec 16;6(3):2100051. doi: 10.1002/gch2.202100051. eCollection 2022 Mar. PubMed PMID: 35284089; PubMed Central PMCID: PMC8902290.
AÑO: 2022; IF: 5.135
Asensi-Canto A, Lopez-Abellan MD, Castillo-Guardiola V, Hurtado AM, Martinez-Penella M, Luengo-Gil G, Conesa-Zamora P. Antitumoral Effects of Tricyclic Antidepressants: Beyond Neuropathic Pain Treatment. Cancers (Basel). 2022 Jul 1;14(13):3248. doi: 10.3390/cancers14133248. PubMed PMID: 35805019; PubMed Central PMCID: PMC9265090.
AÑO: 2022; IF: 6.575

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R